Optiscan Teams up with US Drugmaker to Support FDA Submissions

Optiscan teams up with US drugmaker to support FDA submissions

Optiscan Imaging has inked a game-changing deal with US drugmaker Long Grove to fast-track FDA approvals and unlock new surgical uses for its cutting-edge imaging tech.

Health Check: It’s ‘nothing personal’ as major US biotech fund calls time on Syntara

San Francisco’s BVF Partners has exited all its ASX investments because they are too small for the fund’s mandate Alcidion shares soar 15% on earnings upgrade Optiscan enters “win-win” supplier collab   Syntara (ASX:SNT) CEO Gary Phillips says the exit of a long-term US backer should not be seen as a judgment on the company’s late-stage myelofibrosis drug program. In a block trade the San Francisco BVF Partners has disposed of its $5 million, 6%…

Optiscan inks deal with US pharma firm - Manufacturers' Monthly

Image: Optician Medical imaging company Optiscan Imaging has announced a five-year exclusive collaboration agreement with US-based Long Grove Pharmaceuticals. The agreement is to develop new clinical uses for Long Grove’s intravenous contrast agent, fluorescein sodium (AK-FLUOR®), with Optiscan’s real-time endomicroscopic imaging devices. The partnership brings together Long Grove’s pharmaceutical expertise and manufacturing capabilities with …

Optiscan taps US manufacturer Long Grove Pharmaceuticals for surgical imaging partnership - Australian Manufacturing

Optiscan Imaging has entered a five-year collaboration with US drug manufacturer Long Grove Pharmaceuticals to jointly develop new clinical applications for the fluorescein sodium contrast agent used in surgical imaging.